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Background: Epilepsy is the most common neurological manifestation in individuals
with tuberous sclerosis complex (TSC). However, real-world evidence on diagnosis and
treatment patterns is limited. Here, we present data from TuberOus Sclerosis registry
to increase disease Awareness (TOSCA) on changes in patterns of epilepsy diagnosis,
treatments, and outcomes over time, and detailed epilepsy characteristics from the
epilepsy substudy.
Methods: TuberOus Sclerosis registry to increase disease Awareness (TOSCA) was a
multicentre, international disease registry, consisting of a main study that collected data
on overall diagnostic characteristics and associated clinical features, and six substudies
focusing on specific TSC manifestations. The epilepsy substudy investigated detailed
epilepsy characteristics and their correlation to genotype and intelligence quotient (IQ).
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Results: Epilepsy was reported in 85% of participants, more commonly in younger
individuals (67.8% in 1970s to 91.8% in last decade), while rate of treatments was
similar across ages (>93% for both infantile spasms and focal seizures, except prior
to 1960). Vigabatrin (VGB) was the most commonly used antiepileptic drugs (AEDs).
Individuals with infantile spasms showed a higher treatment response over time with
lower usage of steroids. Individuals with focal seizures reported similar rates of drug
resistance (32.5–43.3%). Use of vagus nerve stimulation (VNS), ketogenic diet, and
surgery remained low.
Discussion: The epilepsy substudy included 162 individuals from nine countries. At
epilepsy onset, most individuals with infantile spasms (73.2%) and focal seizures (74.5%)
received monotherapies. Vigabatrin was first-line treatment in 45% of individuals with
infantile spasms. Changes in initial AEDs were commonly reported due to inadequate
efficacy. TSC1 mutations were associated with less severe epilepsy phenotypes and
more individuals with normal IQ. In individuals with TSC diagnosis before seizure onset,
electroencephalogram (EEG) was performed prior to seizures in only 12.5 and 25% of
subsequent infantile spasms and focal seizures, respectively.
Conclusions: Our study confirms the high prevalence of epilepsy in TSC individuals
and less severe phenotypes with TSC1 mutations. Vigabatrin improved the outcome
of infantile spasms and should be used as first-line treatment. There is, however, still a
need for improving therapies in focal seizures. Electroencephalogram follow-up prior to
seizure-onset should be promoted for all infants with TSC in order to facilitate preventive
or early treatment.
Keywords: epilepsy, registry, TOSCA, TSC, tuberous sclerosis complex
INTRODUCTION
Epilepsy is a common manifestation of tuberous sclerosis
complex (TSC), affecting 80–90% of individuals (1, 2). It usually
presents during the first year of life with infantile (epileptic)
spasms or focal seizures. Focal seizures remain the most frequent
type after the first year of life, but individuals with TSC
may develop almost all seizure types. In about two-thirds of
individuals with TSC, seizures are refractory to anticonvulsant
treatment (3), a much higher proportion than the 23% reported
in the general epilepsy population (4). Epilepsy is associated
with a wide range of TSC-associated neuropsychiatric disorders
(TAND) including intellectual disability (ID), autism spectrum
disorder (ASD), and attention deficit hyperactivity disorder
(ADHD), as well as impaired health-related quality of life
(HRQoL) (5–9).
Treatment options for TSC-associated epilepsy in the first
year of life are specific to infantile spasms because of high rates
and individuals’ responsiveness to vigabatrin (VGB), a first-line
treatment option. Antiepileptic drug (AED) recommendations
in TSC after the age of 1 year are the same as in the general
epilepsy population based on seizure types. Candidates for
epilepsy surgery should be identified early in the course of the
disease. Other non-pharmacological treatment options including
ketogenic diet, and vagus nerve stimulation (VNS) should also
be considered early if the epilepsy is refractory (10). Evidence
supports the use of mammalian target of rapamycin (mTOR)-
inhibitors as adjunctive treatment to AEDs for treating focal
epilepsy in TSC individuals, with a higher response rate in the
younger subgroup aged below 6 years (11–13). Given the early
onset, severity and significant impact of TSC-associated epilepsy
on quality of life (QoL) (3, 5, 6), there is value in longitudinal
population-based studies of detailed epilepsy characteristics.
The TuberOus Sclerosis registry to increase disease Awareness
(TOSCA), which included individuals from 170 sites in
31 countries, was conceived to expand our understanding
of different TSC manifestations, treatment patterns, and
outcomes (14). TuberOus Sclerosis registry to increase disease
Awareness consisted of a main study representing the diagnostic
characteristics and associated clinical features, and six substudies,
each focusing on specific TSC manifestations. In our initial
publication, we reported characteristics of TSC-associated
epilepsies (2). The key observations were (a) a typical onset
pattern of focal seizures and infantile spasms in the first
two years of life, (b), high rates of drug resistance in focal
seizures compared to infantile spasms, and (c) a low proportion
of individuals treated with non-pharmacological therapies,
including epilepsy surgery. Here, we present data from the
TOSCA final analysis, describing rates of epilepsy, treatment
interventions, and outcomes over time. We also report findings
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from the epilepsy substudy, a TOSCA research project, aimed
at reporting more detailed epilepsy characteristics including
time to epilepsy diagnosis, electroencephalogram (EEG) patterns,
and therapies.
METHODS
TuberOus Sclerosis registry to increase disease Awareness
was a multicentre, international disease registry. The study
methods have been reported in detail previously (14). In the
main study, general background information (i.e., demographic
data, family history, pre-natal history, and disease features such
as neurological and neuropsychiatric, renal, cardiovascular,
pulmonary, dermatological, and others) were collected
retrospectively at baseline (first inclusion visit) followed by
prospective data collection during an observation period of
up to 5 years. Follow-up visits were scheduled according
to the standard practice of the site and per the treating
physician’s best judgement, but at minimum intervals of 12
months. Data were retrieved from clinical records, electronic
medical records, individuals’ questionnaires, and ad-hoc clinical
databases. Research projects were designed to record additional,
more detailed data related to specific disease manifestations
[i.e., subependymal giant cell astrocytoma (SEGA), renal
angiomyolipoma, lymphangioleiomyomatosis, genetics, TAND,
QoL, and epilepsy].
Participants and Procedure
Individuals of any age who fulfilled clinical criteria for TSC
diagnosis and a documented clinical visit for TSC within the
past 12 months or newly diagnosed with TSC were enrolled in
the main study. Investigators, specialized in epilepsy care, from
27 sites across nine countries (Belgium, France, Germany, Italy,
Poland, Slovenia, Spain, Japan, and Turkey) participated in the
epilepsy substudy.
Given the observational nature of the study, both diagnostic
and treatment/management were performed according to local
best practice. The study protocol, therefore, did not request any
particular additional clinical or laboratory investigations.
Both main and substudy were designed and conducted
according to the Guidelines for Good Clinical Practice and
ethical principles outlined in the Declaration of Helsinki.Written
informed consent was obtained from all individuals, parents, or
guardians prior to enrolment, with prior endorsement by the
local human research ethics committee.
Data Analyses
From the main study, we present epilepsy characteristics,
emphasizing changes in the rates of epilepsy diagnosis, treatment,
and outcome over time. From the epilepsy substudy, we
report characteristics [age of onset, frequency, tuber numbers,
treatments and treatments outcomes, and intelligence quotient
(IQ) level] of individuals with infantile spasms and focal seizures
and correlated them to genotype. We report the impact of
epilepsy characteristics and EEG foci on intellectual ability, date
of EEG compared to the date of the seizure onset in individuals
with focal seizures and infantile spasms with TSC diagnosis prior
to seizure onset, number of AEDs used at epilepsy diagnosis,
and the reasons for changes in the AED regimen. Intellectual
ability was categorized as normal (IQ > 70), mild ID (IQ
51–70), moderate ID (IQ 36–50), severe ID (IQ 20–35), and
profound ID (IQ< 20). The response of individuals with infantile
spasms was defined as follows: spasm-free + hypsarrhythmia
resolved+ normalized EEG or spasms free with disappearance of
hypsarrhythmia, but persistent EEG anomalies. Efficacy in focal
seizures was defined as >50% decrease in seizure frequency with
rates of seizure freedom and response of >75%.
All eligible individuals enrolled in the TOSCA registry and
epilepsy substudy, without any major protocol deviations,
were included. As the study was observational in nature,
primarily descriptive statistic methods were used. Continuous
variables were evaluated quantitatively (frequency, mean,
standard deviation, median, range), and categorical variables
(presence/absence of a manifestation) were analyzed in terms of
frequency distribution at baseline and at follow-up visits.
RESULTS
Findings From the Final Analysis of the
Main Study
Clinical Characteristics of Epilepsy
Of the 2,211 individuals enrolled in the TOSCA main study,
1,879 (85%) were reported to have epilepsy. Of these, 942
(50.1%) were female and 937 (49.9%) were male (Table 1).
TABLE 1 | Demographics and characteristics of individuals with TSC and epilepsy.
Characteristics Individuals




Age of individuals in years, n (%)
≤2 257 (13.7)
>2 to ≤5 282 (15.0)
>5 to ≤9 311 (16.6)
>9 to ≤14 276 (14.7)
>14 to ≤18 126 (6.7)
>18 to ≤40 499 (26.6)
≥40 128 (6.8)
Type of epilepsy, n (%)
Infantile spasms 735 (39.1)
Focal seizures 1,343 (71.5)
Other seizures 537 (28.6)
Median (range) age at diagnosis, years
Infantile spasms <1 (0–30)
Focal seizures 1 (0–66)
Genetic analysis
Individuals with mutational analysis data available, n (%) 849 (45.2)
TSC1 155 (18.3)
TSC2 587 (69.1)
No mutation identified 107 (12.6)
SD, standard deviation.
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FIGURE 1 | Rates of diagnosis of infantile spasms and focal seizures over time.
Focal seizures were reported in 1,343 individuals (71.5%), while
infantile spasms were reported in 735 (39.1%). Five hundred
and thirty-seven individuals (28.6%) were reported to have
other seizure types. The median age at diagnosis was 1 year
(range 0–66) for focal seizure and <1 year (range 0–30) for
infantile spasms, respectively. Genetic data were available for
849 individuals with epilepsy; 587 (69.1%) had pathogenic
mutations in the TSC2 gene, while 155 (18.3%) had mutations
in the TSC1 gene. In 107 individuals (12.6%), no mutations
were identified.
Epilepsy Diagnosis, Treatment, and Outcome
Patterns Over Time
Epilepsy diagnosis was more common in younger individuals,
ranging from 67.8% in the 1970s to 91.8% in the last decade
(Figure 1, Table 2). The rates of infantile spasms diagnosis
increased from 24.6% in the 1960s to about 41.4% from the 1990s.
The rates of focal seizures diagnosis increased from 29.6% in the
1950s to about 84% in 2000s (Figure 1).
More than 93% reported treatment for infantile spasms or
focal seizures after 1960 (Table 2). Vigabatrin was the most
commonly used AEDs in TSC individuals with infantile spasms
and focal seizures in any year, with usage increasing over time
and a clear shift after the late 1990s (>1950–1960: 33 and 50%;
>1960–1970: 37.5 and 42.3%; >1970–1980: 40.7 and 50.9%;
>1980–1990: 68.2 and 61.8%; >1990–1995: 62.9 and 66.7%,
>1995–2000: 83.3 and 77.1%; >2000–2005: 86.2 and 69.1%;
>2005–2010: 88.1 and 73.3%; >2010–2015: 91.2 and 76.9%). In
contrast, usage of steroids for infantile spasms was at a peak
(reported in 33.9%) between 1990 and 1995, decreasing thereafter
(>1995–2000:16.7%; >2000–2005: 13.8%; >2005–2010: 14.2%;
>2010–2015: 10.0%).
Epilepsy surgery for infantile spasms was reported in only one
of 66 individuals (1.5%) between 1980 and 1990. Epilepsy surgery
appeared as an alternative treatment for infantile spasms since
2000 and reached a peak in recent years (8.0% during 2005 and
2010). In individuals with focal seizures, use of the ketogenic diet
was first reported in two individuals (1.5%) in 1980 with more
regular use since 1995. Use of VNS was first reported in the late
1980s in patients with infantile spasms. Use of VNS showed a
peak at the beginning of the 2000s (reported in 6% of individuals
with infantile spasms and 7.8% in those with focal seizures), but
there was a clear decrease thereafter. In contrast, the ketogenic
diet showed a slow increase since its first use in this cohort but
did not exceed 9% for infantile spasms and 12% for focal seizures.
The use of mTOR inhibitors was reported in 17.1% of individuals
with infantile spasms and 18.1% of individuals with focal seizures
between 2010 and 2015.
Over time, individuals with infantile spasms responded better
to treatment than those with focal seizures (Table 2); those with
infantile spasms achieved a high response rate with a plateau
since the late 1990s. This correlated to an increased use of VGB
and a decreased use of steroids (Figure 2, Table 2). Outcome
of focal seizures did not vary much since the 1960s, plateauing
between 56 and 64% (Table 2).
Findings From the Epilepsy Substudy
A total of 162 individuals (65 adults and 97 children) from 27 sites
across nine countries were enrolled into the epilepsy substudy; 74
(45.7%) were males and 88 (54.3%) were females. Themedian age
at enrolment was 14 years (range 2–63 years). Median duration of
epilepsy prior to enrolment was 12 years (range 1–63 years).
Information about the type of treatment at epilepsy diagnosis
was available in 68 of 71 individuals with infantile spasms and
in 88 of 94 of those with focal seizures; 52 individuals (73.2%)
with infantile spasms and 70 (74.5%) with focal seizures received
monotherapies, while 16 (22.5%) with infantile spasms and 18
(19.1%) with focal seizures received polytherapies.























































N = 20 N = 61 N = 104 N = 183 N = 265 N = 172 N = 241 N = 323 N = 461 N = 380
Individuals ever had epilepsy, n (%) 9 (45.0) 27 (44.3) 69 (66.3) 124 (67.8) 212 (79.7) 152 (88.4) 213 (88.4) 294 (91.0) 430 (93.3) 349 (91.8)
Type of epilepsya
Infantile spasms 0 4 (14.8) 17 (24.6) 29 (23.4) 70 (33.0) 63 (41.4) 80 (37.6) 122 (41.5) 178 (41.4) 172 (49.3)
Focal seizures 5 (55.6) 8 (29.6) 27 (39.1) 57 (46.0) 135 (63.7) 93 (61.2) 168 (78.9) 246 (83.7) 361 (84.0) 243 (69.6)
Other seizures 4 (44.4) 19 (70.4) 42 (60.9) 66 (53.2) 79 (37.3) 64 (42.1) 52 (24.4) 54 (18.4) 84 (19.5) 73 (20.9)
Infantile spasms
Individuals received treatment, n (%) 0 3 (75.0) 16 (94.1) 27 (93.1) 66 (94.3) 62 (98.4) 78 (97.5) 116 (95.1) 176 (98.9) 170 (98.8)
Type of treatment, n (%)b –
VGB 1 (33.3) 6 (37.5) 11 (40.7) 45 (68.2) 39 (62.9) 65 (83.3) 100 (86.2) 155 (88.1) 155 (91.2)
ACTH – 0 3 (18.8) 6 (22.2) 20 (30.3) 21 (33.9) 13 (16.7) 16 (13.8) 25 (14.2) 17 (10.0)
Ketogenic diet – 0 1 (6.3) 0 1 (1.5) 0 2 (2.6) 10 (8.6) 7 (4.0) 13 (7.6)
Fructose derivatives – 0 0 0 0 2 (3.2) 2 (2.6) 3 (2.6) 5 (2.8) 4 (2.4)
Vagus nerve stimulation – 0 0 0 1 (1.5) 2 (3.2) 1 (1.3) 7 (6.0) 7 (4.0) 0
mTOR inhibitors – 0 1 (6.3) 1 (3.7) 4 (6.1) 1 (1.6) 4 (5.1) 4 (3.4) 16 (9.1) 29 (17.1)
Surgery – 0 0 0 1 (1.5) 0 0 9 (7.8) 14 (8.0) 12 (7.1)
Other – 2 (66.7) 13 (81.3) 17 (63.0) 39 (59.1) 35 (56.5) 36 (46.2) 39 (33.6) 83 (47.2) 78 (45.9)
Treatment outcome, n (%)
Resolved spontaneously – 0 1 (6.3) 0 2 (3.0) 7 (11.3) 0 2 (1.7) 9 (5.1) 1 (0.6)
Controlled – 3 (100.0) 9 (56.3) 19 (70.4) 44 (66.7) 43 (69.4) 69 (88.5) 99 (85.3) 138 (78.4) 137 (80.6)
Not-controlled – 0 5 (31.3) 3 (11.1) 14 (21.2) 8 (12.9) 7 (9.0) 12 (10.3) 26 (14.8) 31 (18.2)
Unknown – 0 1 (6.3) 5 (18.5) 6 (9.1) 4 (6.5) 2 (2.6) 3 (2.6) 3 (1.7) 1 (0.6)
Focal seizures
Individuals received treatment, n (%) 5 (100.0) 8 (100.0) 26 (96.3) 53 (93.0) 131 (97.0) 90 (96.8) 166 (98.8) 243 (98.8) 360 (99.7) 238 (97.9)
Type of treatment b
VGB 1 (20.0) 4 (50.0) 11 (42.3) 27 (50.9) 81 (61.8) 60 (66.7) 128 (77.1) 168 (69.1) 264 (73.3) 183 (76.9)
ACTH 0 0 0 1 (1.9) 4 (3.1) 2 (2.2) 3 (1.8) 9 (3.7) 13 (3.6) 9 (3.8)
Ketogenic diet 0 0 0 0 2 (1.5) 0 6 (3.6) 26 (10.7) 16 (4.4) 28 (11.8)
Fructose derivatives 0 0 4 (15.4) 4 (7.5) 8 (6.1) 7 (7.8) 7 (4.2) 15 (6.2) 19 (5.3) 19 (8.0)
Vagus nerve stimulation 0 0 0 2 (3.8) 8 (6.1) 10 (11.1) 8 (4.8) 19 (7.8) 13 (3.6) 3 (1.3)
mTOR inhibitors 0 0 1 (3.8) 9 (17.0) 17 (13.0) 10 (11.1) 24 (14.5) 40 (16.5) 37 (10.3) 43 (18.1)
Surgery 0 0 0 2 (3.8) 8 (6.1) 6 (6.7) 10 (6.0) 25 (10.3) 35 (9.7) 21 (8.8)
Other 5 (100.0) 5 (62.5) 23 (88.5) 39 (73.6) 96 (73.3) 61 (67.8) 116 (69.9) 179 (73.7) 244 (67.8) 166 (69.7)
Treatment outcome, n (%)
Resolved spontaneously 0 0 0 0 0 1 (1.1) 1 (0.6) 2 (0.8) 6 (1.7) 0
Controlled 3 (60.0) 5 (62.5) 18 (69.2) 30 (56.6) 75 (57.3) 50 (55.6) 106 (63.9) 139 (57.2) 212 (58.9) 134 (56.3)
Not-controlled 2 (40.0) 3 (37.5) 7 (26.9) 21 (39.6) 52 (39.7) 39 (43.3) 54 (32.5) 98 (40.3) 137 (38.1) 100 (42.0)
Unknown 0 0 1 (3.8) 2 (3.8) 4 (3.1) 0 5 (3.0) 4 (1.6) 5 (1.4) 4 (1.7)
ACTH, adrenocorticotropic hormone; mTOR, mammalian target of rapamycin; VGB, vigabatrin.
a Individuals may have more than one type of epilepsy.
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FIGURE 2 | Types of intervention over time in individuals with (A) infantile spasms and (B) focal seizures. ACTH, adrenocorticotropic hormone; mTOR, mammalian
target of rapamycin; VGB, vigabatrin.
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Changes of the initial antiepileptic treatment were reported
in 64 (90.1%) individuals with infantile spasms and 64 (68.1%)
with focal seizures. Most frequently reported reasons for change
of treatment were partial or lack of efficacy of the first therapy.
Vigabatrin was used as first-line therapy in individuals with
infantile spasms in less than half of cases (45.1%) and was the
most frequent second line treatment option (62.5%, Table 3).
Characteristics of Epilepsy in TSC by Genotype
Of 63 individuals with available genetic data, 10 had pathogenic
mutations in TSC1 and 53 had pathogenic mutations in TSC2.
Median age of epilepsy onset was 8 years in individuals
with pathogenic variants in TSC1 and <1 year in those with
pathogenic variants in TSC2.
Infantile spasms were not reported in individuals with TSC1,
but in 16 individuals (30.2%) with TSC2. Focal seizures were
reported for most individuals (90% of TSC1 individuals and
69.8% of TSC2 individuals). The median frequency of focal
seizures per week was 3.5 in individuals with pathogenic variants
in TSC1 and 1 in individuals with pathogenic variants in TSC2.
MRI showed a mean number of three tubers in individuals with
TSC1 and 9.2 tubers in in TSC2.
Focal seizures were controlled with treatment in 60% of
individuals with TSC1 compared with only 22.6% of those with
TSC2. Infantile spasms were controlled with treatment in 28.3%
of individuals with TSC2.
Association of Epilepsy Foci With IQ Level
The association between epilepsy and IQ was examined in 102
individuals at baseline (69 had normal intellectual ability and 33
had various degrees of ID). Regarding IQ and focal spikes on last
EEG recording, EEG showed temporal focal spikes in 52.3% of
individuals with normal IQ and frontal focal spikes in 68% of
individuals with moderate to severe ID.
Correlation of IQ Level and Genotype
Sixty-two of 102 individuals showed normal IQ level. The IQ level
was normal in 70% of individuals with TSC1 and in 20.8% of
those with TSC2; moderate ID was found in 20% of individuals
with TSC1 and in 22.6% of those with TSC2; severe ID was
observed in 15.1% of individuals with TSC2, but none of those
with TSC1.
EEG in Individuals With TSC Diagnosis Before
Seizures Onset
Diagnosis of TSC was established in 28 individuals before seizure
onset. In this group, 16 individuals developed infantile spasms
and 12 developed focal seizures. Median age at first EEG was
6 months in individuals with infantile spasms and 11 months
in those with focal seizures. The first EEG was performed
in 12.5% of individuals before the onset of infantile spasms
and in 25% of individuals before the onset of focal seizures.
Electroencephalogram was performed the same day seizures
occurred in 18.8 and 16.7% of individuals with infantile spasms
and focal seizures, respectively. In the remaining cases, 68.8 and
58.3%, EEGwas performed after the onset of infantile spasms and
focal seizures, respectively.
DISCUSSION
This study provides final data or information on epilepsy
characteristics in a large cohort of TSC individuals who
participated in the TOSCA registry and in the epilepsy substudy.
Findings from the main study emphasize the changes in both
diagnosis and treatment patterns of TSC-associated epilepsies
over time. Overall, a diagnosis of epilepsy was reported in
approximately 85% of all individuals with TSC included, equally
affecting both sexes. Infantile spasms were reported in about 39%
of individuals with a median age of <1 year at diagnosis, and
focal seizures in two-thirds of the individuals with a median age
of 1 year at diagnosis. These findings were consistent with our
previous report and also with other studies (2, 3, 15–17).
In our study, epilepsy diagnosis rates, especially diagnosis
of infantile spasms, were higher in younger individuals (67.8%
in 1970s to 91.8% in last decade). Since infantile spasms
were reported as the seizures types of West syndrome by
William West in 1841 (18), followed by Gibbs and Gibbs’
description of the characteristic EEG pattern of hypsarrhythmia
in 1952 (19), clinicians have made remarkable progress in
recognizing this syndrome. The first proposal of classification of
patients with epilepsies in syndromes published in the “Guide
Bleu” (Blue Guide) in 1984 added to this knowledge (20). In
addition, the better recognition of infantile spasms in TSC
and their focal nature might have changed the delineation
of focal seizures and infantile spasms in the recent years.
Although we believe that there was an improvement in the
diagnosis of infantile spasms and that this major improvement
in clinical epileptology guarantees earlier and better seizure
and developmental outcomes. We should be cautious about the
concept of an increased rate of epilepsy diagnosis because older
individuals in TSC clinics often have a lower rate of epilepsy as
they present with angiomyolipoma or being the parent of a child
with TSC.
Our data showed a better treatment response rate in
individuals with infantile spasms over time, but not in those
with focal seizures. This seems to be due to VGB specifity in
infants with West syndrome and its growing usage since the
1990s. A decrease in the use of steroids after VGB also clearly
shows the specific efficacy of VGB and the lack of a need to add
steroids as practiced in infantile spasms due to other etiologies
(21). Vigabatrin is an established first-line therapy for individuals
with infantile spasms (10, 22). This precision medicine approach
in individuals with infantile spasms in TSC is a major example
of how an early diagnosis of TSC can help to better target
the therapy and to avoid therapeutic failures and ineffective
polytherapies. In addition, VGB is recommended as first-line
treatment for focal seizures in individuals with TSC in the first
year of life (10), aiming to prevent transition into infantile
spasms. However, its use for focal seizures in older individuals
does not seem to be superior to other AEDs licensed for focal
seizures. Indeed, there has been no change in responder rates
for focal seizures for the past 45 years despite availability of over
30 new AEDs (23, 24). This finding is also in line with the high
percentage of drug resistance reported in individuals with TSC-
associated focal seizures in recent reports (3, 25). Despite the
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TABLE 3 | Initial and change in the treatment and reason for change in the epilepsy substudy.
Infantile spasms Focal seizures
Number of individuals 71 (43.8) 94 (58.0)
Type of initial treatment reported at the epilepsy diagnosis
Monotherapy 52 (73.2) 70 (74.5)
VGB 32 (45.1) 33 (35.1)
ACTH 8 (11.3) 2 (2.1)
Other 12 (16.9) 33 (35.1)
Polytherapy 16 (22.5) 18 (19.1)
GABAergics and other 5 (7.0) 3 (3.2)
Change of first treatment 64 (90.1) 64 (68.1)
Median time from first to second treatment, days 214.0 (0–5,480) 288.0 (0–8,402)
Type of second treatment
VGB 40 (62.5) 31 (48.4)
ACTH (steroids) 10 (15.6) 3 (4.7)
Ketogenic diet 1 (1.6) 0
Fructose derivates 1 (1.6) 1 (1.6)
Vagus nerve stimulation 0 0
mTOR inhibitors 0 0
Other 42 (65.6) 49 (76.6)
Reason for change of drugs 62 (96.9) 62 (96.9)
Partial efficacy 20 (31.3) 24 (37.5)
No efficacy 20 (31.3) 18 (28.1)
Side effects 1 (1.6) 4 (6.3)
Other 21 (32.8) 16 (25.0)
ACTH, adrenocorticotropic hormone; mTOR, mammalian target of rapamycin; VGB, vigabatrin.
Values are expressed as n (%) unless otherwise mentioned.
high response to VGB in individuals with infantile spasms, it was
not always the first therapy in individuals with infantile spasms
(only 45% received VGB as first-line monotherapy). This finding
is unexpected, especially in epilepsy centers, but emphasizes
the need for more education about the use of individualized
treatment options for specific etiologies.
Surprisingly, other non-pharmacological therapies such as
VNS and the ketogenic diet were not used in this highly
drug resistant population (range 1.5–8.6%). This might be due
to the lack of randomized controlled trials in both therapies
and evidence often based on retrospective small series (26)
from one hand and the lack of expertise in both therapies
on the other hand. The use of VNS in this cohort decreased
during recent years after a peak in the 2000 and might be still
underused although recommended as last resort in patients with
refractory seizures.
Early evaluation for epilepsy surgery candidates in individuals
with drug resistant TSC-associated epilepsies should be
performed in expert centers in order to prevent/minimize
developmental consequences of ongoing seizures (27). In our
study, only a few individuals had epilepsy surgery. However,
we did not ask in the study protocol how many had undergone
pre-surgical evaluation.
Epilepsy surgery shows a relevant rate of 8–10% in our
study but might not reflect yet the number of patients that
were good candidates for epilepsy surgery and that can benefit
from such therapy. Additionally, not all of the epilepsy centers
participating in the study were also surgery centers trained
in TSC-associated epilepsy. Therefore, additional training and
education are needed and additional collaboration with expert
surgery centers should be established for individuals with
drug-resistant epilepsy with TSC in order to promote early
identification of surgery good candidates.
Individuals with TSC and epilepsy are prescribed with
multiple AEDs or undergo multiple surgical procedures to
manage epileptic seizures (28, 29). However, we have observed
in our epilepsy substudy that a large number of individuals were
initiated on AED monotherapies as recommended by the ILAE
(International League Against Epilesy). This might be related to
the use of VGB in the first year of life in both infantile spasms and
focal seizures or epilepsy combining both seizure types.
Our results also showed the increased use of disease-
modifying treatment with mTOR inhibitors. The efficacy of
this therapy was reported in late 2010 and its use in case of
failure of initial treatment could be the rational approach. Its
use increased and reached 18% in the last reports from the
TOSCA study in 2015, showing the need for more efficient
therapies in focal seizures associated with TSC. This increased
use of approved mTOR inhibitor, everolimus, and the wider
evaluation of surgery candidates in the management of TSC-
associated focal seizures and in some individuals with drug-
resistant infantile spasms might improve responder rates in
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the future and could help to achieve a better cognitive
TAND outcomes.
In our substudy, in infants with TSC diagnosis prior to seizure
onset, EEG was performed mainly after the onset of clinical
seizures, both for infantile spasms (in 68.8%) and focal seizures
(in 58.3%). Curatolo et al. recommended in 2012 (22) and later
in 2018 (10) to use EEG in infants with TSC before seizure onset
to early identify individuals at high risk of developing epilepsy.
This was also reported in the international recommendations
(guidelines) in 2013 (30), based on studies showing that TSC
individuals who were diagnosed and treated before the onset of
seizures had less severe epilepsy and better neurodevelopmental
outcomes (31). Abnormal EEG patterns and/or in some instances
subclinical seizures recorded on the EEG should urge the use
of AED therapy without waiting for the onset of overt clinical
seizures. The results of the research project are in contrast
with these recommendations and emphasize the need for more
information for clinicians about the key role of sequential
EEG recordings to early recognize individuals at high risk of
developing early onset seizures and preventive AED treatment.
Parents should be educated to recognize seizures earlier and
most importantly EEG recordings should be performed—with
an ultrasound of cardiac rhabdomyoma, pre-natal, or post-natal
MRIs—in cases with family history of TSC with signs of TSC or
with cutaneous hallmarks of TSC.
The place of this pre-symptomatic diagnosis strategy for
epilepsy in TSC and the preventive therapy might be better
implemented after the recent validation of this approach with the
first results of the EPISTOP study (32, 33). Individuals receiving
early preventive treatment showed a later epilepsy onset and a
less severe epilepsy compared to those receiving standard therapy
started after the onset of clinical seizures. The cognitive outcome
might need further validation and longer follow-up (32, 33).
Our data show no significant correlation between the spikes
focus and the IQ levels as for frontal or temporal focus. More
severe cognitive but mainly psychiatric disorders as ASD are
reported with temporal lesions (34). However, we did not report
ASD testing and TAND results were mostly missing.
Finally, our study showed that individuals with TSC1 had
less severe phenotypes than those with TSC2. This finding is in
accordance with the literature (3, 25, 35), but, importantly, we
were able to validate it on a very large cohort probably less biased
thanmono-center studies and smaller series. A higher proportion
of individuals with TSC1 had normal IQ levels than those with
TSC2. Compared to individuals with TSC2, they had fewer
numbers of tubers, later onset of epilepsy, and higher rates of
controlled seizures. The tuber load, usually higher in individuals
with TSC2, might have a role in creating more complex and
diffuse abnormal networks, with fewer regions showing normal
brain cortex, leading more frequently to drug resistant epilepsy
and higher rates of co-morbidities.
In conclusion, our study highlights that despite the
improvement in diagnosis and in some aspects of treatment
of TSC-associated epilepsy over time, especially for infantile
spasms, there are still some major improvements to be made.
Better epilepsy control is urgently needed, mainly for focal
seizures. A more targeted use of available therapies and the
promotion of innovative therapies and of evaluating surgery
candidates should continue. Despite the established guidelines,
the need for further education of clinicians in order to provide
earlier diagnosis of epilepsy based on serial EEGs before the
onset of seizures in patients with TSC should be promoted and
to use VGB as first monotherapy for infantile spasms established
as the first line therapy. Pre-seizure diagnosis will also help to use
timely or even preventive therapies and could be a major step
toward changing the natural history of epilepsy in individuals
with TSC. Finally, the use of new targeted therapies such as
mTOR inhibitors, or cannabidiol (36), and earlier and better
definition of candidates for epilepsy surgery may lead to better
outcomes, especially for focal seizures where the seizure control
rates have plateaued in the last decade.
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